Clinical Trials · NCT00191867

Clinical Trial of Teriparatide in Japan

CompletedPhase 2Teriparatide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
160
Start date
Feb 2005
Locations
6 sites, Japan
Primary endpoint
To assess the dose response of LY333334 with the percent change from baseline in lumbar spine mineral density at endpoint
View Teriparatide compound reference